Indeed, the use of antisense or rybozyme targeting MDR-1 gene has led to the sensitization of acute myeloid leukemia (AML), ovarian, colon, and breast cancer cells to doxorubicin as well as to increase the sensitivity of chronic and AML cells to daunorubicin [16,17]. This evidence concerns the gene ABCB1 and breast cancer.